In-Depth Study of Segments, Industry Developments, and Key Players in the Cardiovascular Genetic Testing Market

The cardiovascular genetic testing market is on the brink of significant expansion, driven by advances in precision medicine and growing integration of genomics into healthcare. As genetic insights become more accessible, this field is poised to transform how cardiovascular diseases are predicted, diagnosed, and treated. Let's explore the market size, key players, emerging trends, and segment breakdowns shaping this evolving industry.

Projected Growth and Market Size of Cardiovascular Genetic Testing
The cardiovascular genetic testing market is anticipated to expand rapidly, reaching a value of $6.62 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 11.0%. Several factors contribute to this upward trajectory, including heightened demand for precision medicine strategies, the widespread adoption of population-based genetic screening, and the increasing use of AI-driven variant interpretation technologies. Furthermore, a stronger focus on integrating genomics into clinical decision-making and preventive cardiovascular healthcare continues to propel the market forward. Important trends expected to influence the market include greater use of predictive genetic risk assessments, multigene panel testing, bioinformatics combined with AI analytics, expanding pharmacogenomic applications, and the increasing personalization of cardiovascular care.

Download a free sample of the cardiovascular genetic testing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33054&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Feb_PR

Leading Players in the Cardiovascular Genetic Testing Industry
The competitive landscape of the cardiovascular genetic testing market is shaped by several prominent companies. Key players include Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.
A notable example of strategic growth occurred in February 2025, when US-based precision medicine company Tempus AI Inc. acquired Ambry Genetics, a firm specializing in cardiovascular genetic testing. This acquisition strengthens Tempus AI's efforts to combine diagnostics and data analytics, enhancing their ability to offer advanced solutions to clinicians, patients, and life science entities.

Key Drivers Accelerating Growth in Cardiovascular Genetic Testing
The market is increasingly propelled by the development of clinician-ordered genetic tests designed to ensure medical necessity and reduce unnecessary procedures. These tests are tailored to the patient's individual health needs, optimizing healthcare costs and outcomes.
For instance, in September 2025, Mass General Brigham, in partnership with Broad Clinical Labs and Mass General Brigham Laboratory for Molecular Medicine, launched a genetic test evaluating inherited risk for eight cardiovascular conditions. This self-pay test assesses predisposition to ailments such as atrial fibrillation, coronary artery disease, type 2 diabetes, and hypertension, among others. The test was developed using genotype and clinical data from over 236,000 participants from the NIH's All of Us Research Program. It combines publicly available polygenic risk scores through an elastic-net modeling approach called PRSmix. High-resolution genome-exome sequencing is performed at Broad Clinical Labs, with results interpreted by the CLIA-certified Mass General Brigham laboratory, which also produces patient-friendly reports.

View the full cardiovascular genetic testing market report:
https://www.thebusinessresearchcompany.com/report/cardiovascular-genetic-testing-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Feb_PR

Emerging Trends and Innovations Influencing the Market
Innovation is a key focus as companies strive to develop advanced, data-driven testing solutions that improve diagnostic accuracy and patient care. The incorporation of AI and bioinformatics is expanding capabilities for genetic variant interpretation, leading to more personalized and actionable insights for cardiovascular diseases.
Moreover, pharmacogenomic testing is gaining traction, providing critical information on drug response, adverse reaction risk, and dose optimization tailored to individual genetic profiles. This personalized approach aims to enhance treatment efficacy and safety for cardiovascular patients.

Breakdown of Major Segments in the Cardiovascular Genetic Testing Market
The market is categorized across several dimensions to provide a comprehensive understanding:
1) Testing Types: Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, and Other Testing Types.
2) Diseases Addressed: Inherited Cardiomyopathies, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Arrhythmia, Aortopathies, and Other Diseases.
3) Technologies Utilized: Cytogenetic Testing, Biochemical Testing, and Molecular Testing.
4) Applications: Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, and Other Applications.
5) End Users: Hospitals and Clinics, Diagnostic Laboratories, Research Institutions, Genetic Counseling Centers, Pharmaceutical Companies, and Direct-To-Consumer Testing.

Detailed Subcategories Within Testing Types
Each testing type includes further subdivisions, such as:
- Predictive Testing: presymptomatic risk assessment, familial variant screening, polygenic risk evaluation, late-onset disease prediction, and susceptibility gene testing.
- Carrier Testing: autosomal recessive carrier screening, linked carrier screening, expanded carrier panels, single gene carrier screening, and family history-based carrier testing.
- Prenatal and Newborn Testing: non-invasive prenatal testing, invasive prenatal diagnostics, newborn metabolic screening, congenital heart disease genetic screening, and neonatal gene panel testing.
- Diagnostic Testing: single gene diagnostics, multigene panel diagnostics, whole exome and whole genome diagnostics, and variant confirmation testing.
- Pharmacogenomic Testing: drug response gene testing, adverse drug reaction risk testing, dose optimization, anticoagulant response testing, and cardiovascular drug metabolism testing.
- Other Testing Types: cascade family testing, population-based screening, research-use testing, confirmatory follow-up tests, and clinical trial genetic testing.

This detailed segmentation highlights the market's complexity and the wide range of testing approaches used to address cardiovascular genetic health comprehensively.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.